Core Viewpoint - Heptagon Pharmaceuticals-B (02142.HK) announced a share buyback of 250,000 shares at a cost of HKD 3.34 million on October 13 [1] Group 1 - The company executed a buyback program, indicating confidence in its stock value [1] - The total expenditure for the buyback was HKD 3.34 million [1] - The number of shares repurchased was 250,000 [1]

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 02142 | 說明 | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | 庫存股份變動 | | | | | 事件 | 已發行股份（不包括庫存股份）數 目 | 佔有關事件前的現有已發 行股份（不包括庫存股 份）數目百分比 (註3) | 庫存股份數目 | 每股發行/出售價 (註4) | 已發行股份總數 | ...

Investment Rating - Industry Rating: Outperform the Market (maintained rating) [5] Core Insights - The 2025 Nobel Prize in Physiology or Medicine was awarded for groundbreaking discoveries in "peripheral immune tolerance," highlighting the development potential of regulatory T cells (Treg) in autoimmune diseases, cancer, and organ transplantation [1][2] - Key research findings include the identification of Treg cells by Shimon Sakaguchi in 1995 and the discovery of the FOXP3 gene's role in Treg development and function by Mary E. Brunkow and Fred Ramsdell in 2001 [2] - The "peripheral immune tolerance" mechanism offers therapeutic avenues for various diseases, including enhancing Treg function for autoimmune diseases, inhibiting Treg activity in cancer to allow immune system attacks on tumors, and improving organ transplant acceptance [3] Summary by Sections - **Therapeutic Development**: Multiple therapies targeting the Treg mechanism are currently undergoing clinical validation, with companies like RegCell and Sonoma Biotherapeutics founded by the awarded scientists focusing on Treg therapies [4] - **Market Opportunities**: Chinese companies such as Cellin Biotech and Bionautics are also entering this field, targeting diseases like amyotrophic lateral sclerosis and rheumatoid arthritis through Treg therapies [4] - **Targeted Therapy Challenges**: The main challenge in Treg-targeted therapies is selectivity, requiring drugs to distinguish between harmful tumor-infiltrating Tregs and beneficial peripheral Tregs [4] - **Investment Recommendations**: Companies to watch include Lixin Pharmaceutical (CCR8 antibody LM-108), Kangyuan Pharmaceutical (CCR8 antibody KYS2301), and others developing CTLA-4 and CCR8 antibodies [5]

格隆汇10月10日丨和铂医药-B(02142.HK)公告，10月10日耗资284万港元回购20万股。 ...

和铂医药-B(02142)公布，2025年10月10日耗资约284.02万港元回购20万股股份。 ...

智通财经APP讯，和铂医药-B(02142)公布，2025年10月10日耗资约284.02万港元回购20万股股份。 ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 和鉑醫藥控股有限公司 呈交日期： 2025年10月10日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 02142 | 說明 | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | 庫存股份變動 | | | | 事件 | | 已發行股份（不包括庫存股份）數 目 | 佔有關事件前的現有已發 行股份（不包括庫 ...

Summary of Key Points Core Viewpoint - On October 9, 30 Hong Kong-listed companies conducted share buybacks, totaling 17.93 million shares and an aggregate amount of HKD 621 million [1][2]. Group 1: Buyback Details - Tencent Holdings repurchased 816,000 shares for HKD 551 million, with a highest price of HKD 680.50 and a lowest price of HKD 666.00, bringing its total buyback amount for the year to HKD 60.41 billion [1][2]. - Guoquan repurchased 4.72 million shares for HKD 14.99 million, with a highest price of HKD 3.21 and a lowest price of HKD 3.07, totaling HKD 150.42 million for the year [1][2]. - Jinsong Machine Tool China repurchased 330,000 shares for HKD 11.12 million, with a highest price of HKD 33.98 and a lowest price of HKD 33.40, totaling HKD 17.49 million for the year [1][2]. Group 2: Buyback Rankings - The highest buyback amount on October 9 was from Tencent Holdings at HKD 551 million, followed by Guoquan at HKD 14.99 million [1][2]. - In terms of share quantity, Guoquan led with 4.72 million shares repurchased, followed by China Electric Valley and Lianyi Rong Technology with 3.10 million and 2.14 million shares, respectively [1][2]. Group 3: Additional Buyback Information - Notably, the buyback by Zhaogang Group-W on this date marked its first buyback of the year [2]. - The overall buyback activity reflects a trend among companies to utilize share repurchases as a strategy to enhance shareholder value [1][2].

智通财经APP讯，和铂医药-B(02142)发布公告，该公司于2025年10月9日斥资75.99万港元回购5万股股 份，每股回购价格为14.96-15.33港元。 ...

和铂医药-B(02142)发布公告，该公司于2025年10月9日斥资75.99万港元回购5万股股份，每股回购价格 为14.96-15.33港元。 ...